港股續跌藍籌個別發展 平保國壽尋底 海底撈升9%
恆指六連跌累挫半成後,今天仍反覆受壓,早段曾升至16,247無以爲繼,午後初段曾跌153點,低見16,036,現報16,101,跌88點或0.5%,總成交額654億元。
藍籌股以康師傅(00322.HK)走勢較差,三連跌兼創逾三年半低,現報8.63元,跌4.1%。百威亞太(01876.HK)回落3.5%報13.12元。聯想(00992.HK)回吐2.8%現報10.32元,失10天及20天線。小米(01810.HK)連跌第四天,最低見13.84元(暫守百天線13.8元),現報14.04元,續跌2%。
中芯(00981.HK)連跌第八天,最低見17元、創近十個月低,現報17.08元,續跌3%。此外,京東健康(06618.HK)連跌第八天,最低見31.55元(暫守2022年3月所創上市低位31.4元),現報31.7元,續跌2.5%。
金融股以保險股沽壓較大,中國平安(02318.HK)及國壽(02628.HK)分別連跌第七天及連跌第五天,同創逾一年低,現報31.6元及8.9元,續跌近2%;友邦(01299.HK)低見61.25元(暫守去年9月下旬所創52周低位61.15元),現報62.4元,跌1.9%。中銀香港(02388.HK)連跌第七天、兼創近八年低,現報19.74元,續跌1.8%。
權重股騰訊(00700.HK)及阿里(09988.HK)分別連跌第五天及連跌第四天,現報279.4元及69.05元,跌1.5%及1%。
然而,獲麥格理上調盈利預測的海底撈(06862.HK)連升第二天,重越10天及20天線,午後高見14.54元,現報14.52元,續升9%。美團(03690.HK)回升1.7%報71.75元。
大和建議「持有」的藥明生物(02269.HK)連升第二天,最高見28.15元,現報28.05元,續升6.5%。國藥(01099.HK)、中生(01177.HK)、翰森(03692.HK)及藥明康德(02359.HK)升逾近1%-2%。
出口股申洲(02313.HK)及創科(00669.HK)升1.9%-2%,現報75.4元及87.8元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.